drugset / Trial / NCT00171106

Efficacy and Safety of Valsartan Versus Placebo on Exercise Tolerance in Patients With Heart Failure

NCT00171106 ↗

Phase 4 Completed 150 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will test the effects of valsartan versus placebo on exercise tolerance in patients with symptoms of heart failure

Timeline

Start
2002-12
Primary completion
2007-08
Completion
2008-02

Outcome

Missed primary endpoint

paper Valsartan had no significant effect on exercise time (primary variable), PMID 19789402 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Valsartan Unknown 320 mg —